Early in my career I contributed to a number of publications. Later as my roles changed and I worked for CROs, my work has been of a similar nature, however, I have been contributing to presentations in reviewer roles and leaving authorship to those experts in the primary subject of the papers.

Full Papers;

Fracture rate and back pain during and after discontinuation of teriparatide: 36 month data from the European Forsteo Observational Study (EFOS) Astrid Fahrleitner-Pammer, Bente L. Langdahl, Fernando Marin, Franz Jakob, Dimitrios Karras, Annabel Barrett, Östen Ljunggren, J. Bernard Walsh, Gérald Rajzbaum, Clare Barker, Willem F. Lems Ost. International, <accepted for publication in October 2010 >

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
A. Blumsohn & F. Marin & T. Nickelsen & K. Brixen & G. Sigurdsson & J. González de la Vera & S. Boonen & S. Liu-Léage & C. Barker & R. Eastell Osteoporos Int August 2010, DOI 10.1007/s00198-010-1379-y

Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS
George Lyritisa, Fernando Marin, Clare Barker, Michael Pfeiferc, Jordi Farreronsd, Kim Brixene, Javier del Pinof, Richard Keeng, Thomas N. Nickelsen CMRO, August 2010, Vol. 26, No. 8 , Pages 1799-1807

Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Post-menopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS).
Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren Ö, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F. Calcified Tissue Int DOI 10.1007/s00223-009-9299-6 (online 13-Oct-2009).

Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS) Richard Eastell, Thomas Nickelsen, Fernando Marin, Clare Barker, Peyman Hadji, Jordi Farrerons, Maurice Audran, Steven Boonen, Kim Brixen, Jose Melo Gomes, Barbara Obermayer-Pietsch, Avraam Avramidis, Gunnar Sigurdsson and Claus C Glüer
Journal of Bone and Mineral Research Apr 2009, Vol. 24, No. 4, Pages 726-736: 726-736.

Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment Barbara M Obermayer-Pietsch, Fernando Marin, Eugene V McCloskey, Peyman Hadji, Jordi Farrerons, Steven Boonen, Maurice Audran, Clare Barker, Athanasios D Anastasilakis, William D Fraser, Thomas Nickelsen and for the EUROFORS Investigators
Journal of Bone and Mineral Research Oct 2008, Vol. 23, No. 10, Pages 1591-1600: 1591-1600.

Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis Steven Boonen, Fernando Marin, Barbara Obermayer-Pietsch, Maria E. Simões, Clare Barker, Emmett V. Glass, Peyman Hadji, George Lyritis, Heide Oertel, Thomas Nickelsen, Eugene V. McCloskey for the EUROFORS Investigators J. Clin. Endocrinol. Metab., Mar 2008; 93: 852 - 860.

Monitoring Teriparatide-Associated Changes in Vertebral Microstructure by High-Resolution CT In Vivo: Results From the EUROFORS Study Christian Graeff, Wolfram Timm, Thomas N Nickelsen, Jordi Farrerons, Fernando Marín, Clare Barker, Claus C Glüer and for the EUROFORS High Resolution Computed Tomography Substudy Group
Journal of Bone and Mineral Research Sep 2007, Vol. 22, No. 9, Pages 1426-1433: 1426-1433.

Abstracts, Posters and Orals;

Karras D, Drossinos V, Barker C, Korelis E, Hellenic EFOS study group. Compliance, fracture incidence, health-related quality of life and back pain outcome in Greek postmenopausal women who initiate Teriparatide: 18 month results from a European Forsteo Observational Study (EFOS). 21st Annual French Congress of Rheumatology 2008.

Langdahl BL, Ljunggren O, Lems WF, Walsh JB, Barker C, Fahrleitner-Pammer A, Karras D, Rajzbaum G, Jakob F, Kutahov A, Marin F. Fracture incidence and changes in quality of life and back pain in women with osteoporosis treated with rhPTH(1-34) (teriparatide): 18 months results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2008; 82(Suppl 1):S158.

Lems WF, Langdahl BL, Ljunggren O, Kutahov A, Karras D, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Barker C, Jakob F, Marin F. Fracture incidence, quality of life and back pain in women with osteoporosis pretreated with bisphosphonates: 18 month results from the European Forsteo Observational Study (EFOS). Arthritis Rheum 2008; 58(9 Suppl A):S737.

Ljunggren O, Fahrleitner-Pammer A, Kutahov A, Walsh JB, Langdahl BL, Jakob F, Lems WF, Rajzbaum G, Barker C, Karras D, Marin F. Back Pain is Reduced in Postmenopausal Women with Severe Osteoporosis Treated with rhPTH(1-34) (teriparatide) Regardless of Incident Fractures: 18 Month Results from the European Forsteo Observational Study (EFOS). J Bone Miner Res 2008; 23:S347.

Langdahl BL, Ljunggren O, Lems WF, Walsh JB, Barker C, Fahrleitner-Pammer A, Karras D, Rajzbaum G, Jakob F, Kutahov A. Women with Severe Osteoporosis Treated with rhPTH(1-34) (teriparatide) Improve Quality of Life Regardless of Incident Fractures: 18 Month Results from the European Forsteo Observational Study (EFOS). J Bone Miner Res 2009; 23:S347.

Lems WF, Langdahl BL, Ljunggren O, Barrett A, Karras D, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Barker C, Jakob F, Marin F. Fracture incidence, quality of life and back pain in women with osteoporosis pretreated with bisphosphonates: 18 month results from the European Forsteo Observational Study (EFOS). Osteoporos Int 2009; 20(Suppl 1):S75.

Hadji P, Nickelsen T, Marin F, Farrerons J, McCloskey EV, Audran M, Boonen S, Anastasilakis A, Barker C, Obermayer-Pietsch BM. Bone mineral density response to 2 years of continuous treatment with teriparatide: final results from the Eurofors study. Osteoporos Int (2007); 18(Suppl 1):S7.

Obermayer-Pietsch BM, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Anastasilakis A, McCloskey E. Response of BMD to 24 months of teriparatide (rhPTH 1-34) in patients with and without prior antiresorptive treatment: Final results from the EUROFORS Study. J Bone Miner Res (2006); 21(Suppl 1):S43.

McCloskey EV, Marin F, Obermayer-Pietsch BM, Simoes ME, Barker C, Lyritis G, Oertel H, Nickelsen TN, Boonen S. Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis: final results from the Eurofors trial. Calcif Tissue Int (2007); 80(Suppl 1):30.

J. Walsh, W. Lems, D. Karras, B. Langdahl, O. Ljunggren, C. Barker, A. Fahrleitner-Pammer, A. Barrett, G. Razjbaum, F. Jakob, F. Marin. Fracture Incidence, Quality of Life and Back Pain in Elderly Women with Osteoporosis Treated with Teriparatide: 18-Month Results from the European Forsteo Observational Study (EFOS). ASBMR 2009.